The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Abritalin E.Yu.

Almazov National Medical Research Centre

Khabarov I.Yu.

Almazov National Medical Research Centre

Antidepressants in psychiatric practice

Authors:

Abritalin E.Yu., Khabarov I.Yu.

More about the authors

Read: 1938 times


To cite this article:

Abritalin EYu, Khabarov IYu. Antidepressants in psychiatric practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):126‑132. (In Russ.)
https://doi.org/10.17116/jnevro2024124061126

Recommended articles:
The gut microbiota in bipo­lar diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
Subjective sleep quality evaluation in patients with neuromyelitis optica spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):57-61
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
Impact of various reha­bilitation programs on anxiety and depression after surgery of early-stage cervical cancer. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):40-44

References:

  1. Drobizhev MYu, Serdyuk OV, Ovchinnikov AA, et al. Pathogenetic and pharmacological approach to the choice of antidepressants. Sotsial’naya i klinicheskaya psikhiatriya. 2014;24(2):86-91. (In Russ.).
  2. Drobizhev MYu, Ovchinnikov AA, Kikta SV. Mechanisms of actions of antidepressants and pathogenesis of psychiatric disorders. What is conformities? Sotsial’naya i klinicheskaya psikhiatriya. 2017;27(3):94-101. (In Russ.).
  3. Qaseem A, Owens DK, Etxeandia-Ikobaltzeta I, et al. Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians. Annals of Internal Medicine. 2023;176(2):239-252.  https://doi.org/10.7326/M22-2056
  4. Karkusova MD. Biological effects of serotonin (review article). Vestnik novykh meditsinskikh tekhnologiy. E-edition. 2022;16(6):133-139. URL: https://doi.org/10.24412/2075-4094-2022-6-3-12
  5. Bykov YuV, Bekker RA. Agomelatine: extended indications for its use in psychiatry, neurology and substance abuse medicine. Psihiatrija i psihofarmakoterapija. 2018;20(3-4):4-18. (In Russ.).
  6. Alvano SA, Zieher LM. An updated classification of antidepressants: A proposal to simplify treatment. Personalized Medicine In Psychiatry. 2020;19-20:1-14.  https://doi.org/10.1016/j.pmip.2019.04.002
  7. Vasil’eva AV, Karavaeva TA, Zinchenko YuP, et al. Generalizovannoe trevozhnoe rasstroistvo: Klinicheskie rekomendatsii. Vzroslye. Elektronnoe izdanie. M.: Ministerstvo zdravookhraneniya Rossiiskoi Federatsii, 2021. 101 s. Ssylka aktivna na 30.04.24. (In Russ.). https://cr.minzdrav.gov.ru/schema/457_2
  8. Beburishvili AA, Vasil’eva AV, Gantman MV, et al. Panicheskoe rasstroistvo: Klinicheskie rekomendatsii. Vzroslye. Elektronnoe izdanie. M.: Ministerstvo zdravookhraneniya Rossiiskoi Federatsii, 2021. 113 s. Ssylka aktivna na 30.04.24. (In Russ.). https://cr.minzdrav.gov.ru/recomend/456_2
  9. Karavaeva TA, Vasil’eva AV, Zinchenko YuP, et al. Trevozhno-fobicheskie rasstroistva u vzroslykh: Klinicheskie rekomendatsii; Rossiiskoe obshchestvo psikhiatrov. M.: Ministerstvo zdravookhraneniya Rossiiskoi Federatsii, 2021. 65 s. Ssylka aktivna na 30.04.24. (In Russ.). https://cr.minzdrav.gov.ru/schema/455_2
  10. Karavaeva TA, Vasil’eva AV, Idrisov KA, et al. Posttravmaticheskoe stressovoe rasstroistvo. Klinicheskie rekomendatsii. Vzroslye. Elektronnoe izdanie. M.: Ministerstvo zdravookhraneniya Rossiiskoi Federatsii, 2023. 200 s. Ssylka aktivna na 30.04.24. (In Russ.). https://cr.minzdrav.gov.ru/schema/753_1
  11. Akhapkin RV, Bukreeva ND, Vazagaeva TI, et al. Depressivnyi epizod, Rekurrentnoe depressivnoe rasstroistvo: Klinicheskie rekomendatsii. Vzroslye. Elektronnoe izdanie. M.: Ministerstvo zdravookhraneniya Rossiiskoi Federatsii, 2021. 101 s. Ssylka aktivna na 30.04.24. (In Russ.). https://cr.minzdrav.gov.ru/recomend/301_2
  12. Kostyukova EG, Mazo GE, Fedorova EYu, et al. Bipolyarnoe affektivnoe rasstroistvo: Klinicheskie rekomendatsii. Vzroslye. Elektronnoe izdanie. M.: Ministerstvo zdravookhraneniya Rossiiskoi Federatsii; 2021. Ssylka aktivna na 30.04.24. (In Russ.). https://cr.minzdrav.gov.ru/recomend/675_1
  13. Petrova NN, Semenova NV. Prescription of psychotropic drugs off label. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7):130-135. (In Russ.). https://doi.org/10.17116/jnevro2023123071130
  14. Popov MYu, Kozlovskii VL. Antidepressivnaya terapiya pri depressivnykh i trevozhnykh rasstroistvakh, komorbidnykh somaticheskoi patologii: uchebnoe posobie. M.—SPb.: SPb NIPNI im. V.M. Bekhtereva; 2015. (In Russ.).
  15. Cuijpers P, Miguel C, Harrer M, et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 2023;22(1):105-115.  https://doi.org/10.1002/wps.21069
  16. Fava GA, Gatti A, Belaise C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychotherapy and Psychosomatics. 2015;84:72-81.  https://doi.org/10.1159/000370338
  17. Petrova NN. Generics in psychiatric practice: focus on antidepressants. Sovremennaya terapiya v psikhiatrii i nevrologii. 2023;3-4:5-12. (In Russ.).
  18. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Sertralin Kanon, LP-№(002924)-(RG-RU) ot 02.08.2023 g. Ssylka aktivna na 30.04.2024. (In Russ.). https://canonpharma.ru/upload/iblock/0c3/knsau62cjy6ex2f746auwbxby96zk20b.pdf
  19. Akzhigitov RG, Alekyan BG, Alferova VV, et al. Ishemicheskii insul’t i tranzitornaya ishemicheskaya ataka u vzroslykh. Klinicheskie rekomendatsii. Vzroslye. Elektronnoe izdanie. M.: Ministerstvo zdravookhraneniya Rossiiskoi Federatsii, 2021. 260 s. Ssylka aktivna na 30.04.24. (In Russ.). https://cr.minzdrav.gov.ru/recomend/171_2
  20. Drekher Ya. Psikhofarmakoterapiya. Spravochnik; per s nem.; pod obshch. Red. Prof. Neznanova N.G. M.: MEDpress-inform; 2020. (In Russ.).
  21. Neznanov NG, Samushiya MA, Mazo GE, et al. Algoritmy diagnostiki i terapii psikhicheskikh rasstroystv, registriruyemykh v period pandemii COVID-19: uchebnoye posobiye. M.: Tsentral’naya gosudarstvennaya meditsinskaya akademiya Upravleniya delami Prezidenta Rossiyskoy Federatsii; 2021. (In Russ.).
  22. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Fluoksetin Kanon, LP-№(00352)-(RG-RU) ot 21.03.2019 g. Ssylka aktivna na 30.04.24. (In Russ.). https://canonpharma.ru/upload/iblock/dfb/dfb91d1a67a5356913ef48154f4c908d.pdf
  23. Asadullin AR, Akhmetova EA, Efremov IS, Abdrakhmanova AE. Psikhofarmakoterapiya dlya praktikuyushchikh narkologov: rukovodstvo dlya vrachei. M.: MEDtressinform; 2023. (In Russ.).
  24. Fluoksetin (Fluoxetine) instruktsiya po primeneniyu. Spravochnik lekarstvennykh sredstv Vidal (elektronnyi resurs). Ssylka aktivna na 30.04.24. (In Russ.). https://www.vidal.ru/drugs/fluoxetine__13699
  25. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression — lack of manic induction. J Affect Disord. 2005;87(1):121-130.  https://doi.org/10.1016/j.jad.2005.02.018
  26. Zhou X, Keitner GI, Qin B, et al. Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis. Int J Neuropsychopharmacol. 2015;25;18(11):pyv060. https://doi.org/10.1093/ijnp/pyv060
  27. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Estsitalopram Kanon, LP-№(003471)-(RG-RU) ot 02.03.2021 g. Ssylka aktivna na 30.04.24. (In Russ.). https://canonpharma.ru/upload/iblock/ee7/ee78b7720caf1350761e5ffbd582783d.pdf
  28. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Duloksetin Kanon, LP-№(002148)-(RG-RU) ot 18.07.2018 g. Ssylka aktivna na 30.04.24. (In Russ.). https://canonpharma.ru/upload/iblock/1a6/1a6df7074cec0dd705e69e471fdf3218.pdf
  29. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Mirtazapin Kanon LP-№(004694)-(RG-RU) ot 21.02.2024 g. Ssylka aktivna na 30.04.24. (In Russ.). https://canonpharma.ru/upload/iblock/679/6790adca662db7801acc191f324eba5b.pdf
  30. Bykov YuV, Bekker RA, Reznikov MK. Depressii i rezistentnost’. Prakticheskoe rukovodstvo dlya vrachei. M.: RIOR: INFRA-M.; 2013. (In Russ.).
  31. Stahl SM. Stahl’s Essential Psychopharmacology: The Prescribers Guide, 7th Edition. Cambridge University, New York. 2020.
  32. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Agomelatin Kanon, LP-№(002979)-(RG-RU) ot 10.08.2023 g. Ssylka aktivna na 30.04.24. (In Russ.). https://www.rlsnet.ru/drugs/agomelatin-kanon-89740?ysclid=lvnzeqcoiv898739762
  33. Cao B, Xu L, Chen Y, et al. Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. CNS Spectrums. 2021. https://doi.org/10.1017/S1092852921000171
  34. Petrova NN. New goals for depression therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11):57-61. (In Russ.). https://doi.org/10.17116/jnevro202212211157
  35. Abritalin EYu. About the causes and therapy of depressive disorders in COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8):87-92. (In Russ.). https://doi.org/10.17116/jnevro202112108187
  36. Volel BA. Safety and efficacy of agomelatine in the treatment of anxiety and depressive disorders in clinical practice (based on OCTAVA protocol). Psihiatrija i Psihofarmakoterapija. 2015;17(2):9-14. (In Russ.).
  37. Billioti de Gage S, Collin C, et al. Hepatotoxicity of agomelatine and other antidepressants versus selective serotonin reuptake inhibitors. European Neuropsychopharmacology. 2017;27(4):844.  https://doi.org/10.1016/S0924-977X(17)31518-3

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.